Spur Therapeutics announced it will present new clinical data for avigbagene parvec (FLT201), its Phase 3-ready gene therapy candidate for Gaucher disease, at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress being held October 7-10, 2025, in Seville, Spain.
Clinical Data Presentation Details
The poster presentation, titled "Long-term durability of FLT201: an investigational gene therapy for Gaucher disease Type 1 encoding an engineered variant of the GCase enzyme," will be presented by Pilar Giraldo, MD, PhD, from Hospital Universitario Quironsalud in Zaragoza, Spain. The presentation is scheduled for Wednesday, October 8, 2025, from 14:00-15:30 CEST (8:00-9:30 a.m. EST) under poster number P0979 in the metabolic diseases category.
Gene Therapy Approach for Gaucher Disease
FLT201 represents a gene therapy approach that encodes an engineered variant of the GCase enzyme, targeting Gaucher disease Type 1. The therapy is designed to address the underlying genetic deficiency that characterizes this metabolic disorder. The focus on long-term durability data suggests the company has accumulated substantial follow-up information on the therapy's sustained effects in patients.
Company Development Pipeline
Spur Therapeutics positions itself as a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. The company's approach involves optimizing every component of its product candidates to unlock the true potential of gene therapy and achieve outsized clinical results.
Beyond Gaucher disease, Spur is also advancing a preclinical gene therapy candidate for Parkinson's disease, indicating the company's broader commitment to addressing neurological and metabolic disorders through genetic medicine approaches.
